Medi-Span’s Price Alert (correction)
Executive Summary
Average wholesale pricing database Price Alert is owned by Medi-Span, not First DataBank. "The Pink Sheet" incorrectly reported the owner of Price Alert in a story on Pfizer/Boehringer Ingelheim's chronic obstructive pulmonary disease therapy Spiriva (1"The Pink Sheet" May 31, 2004, p. 14)...
You may also be interested in...
Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD
Pfizer and Boehringer Ingelheim are launching the chronic obstructive pulmonary disease therapy Spiriva at a 30% discount to the average wholesale price of GlaxoSmithKline's Advair
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.